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In this issue of the journal, Steinwald et al [1] extend
limited clinical studies and report an animal experiment
showing that calcitonin precursors (predominantly procal-
citonin) are elevated in proportion to the severity of bacte-
rial sepsis. They conclude that procalcitonin, the major
calcitonin precursor, is a good indicator of the activity and
severity of the inflammatory response and may be used for
monitoring bacterial infections.
In recent years, a variety of laboratory and immunologic
parameters have been proposed as possible indicators of
severe inflammatory response to infections. One such
parameter is procalcitonin, which has emerged as a pos-
sible marker of severe generalized infections [2]. The
exact role of procalcitonin during infection is unclear.
The elevated amount found during sepsis does not lead
to increased levels of calcitonin and there is, as yet, no
evidence that it may be involved in calcium metabolism.
Also, its exact site of production during sepsis is unclear;
however, recent research suggests that the monocytes
may be one possible source during sepsis. Despite the
unknown (and potentially very important) patho-
physiology of procalcitonin during sepsis, much clinical
research has focused on using procalcitonin as a marker
of the inflammatory response to severe generalized
infections.
Why is it important to have markers of infection?
Although a recent concensus conference has set up new
definitions and diagnostic criteria of sepsis, two major
problems remain. First, uncontrolled infections are not the
only cause of systemic inflammation and other stimuli
such as pancreatitis, major trauma, and thermal injury can
also trigger a systemic inflammatory response. In the
clinic, therefore, it is frequently difficult to decide on the
aetiology of an inflammatory response syndrome and
direct appropriate therapy. Second, the disappointing
results of immunomodulatory trials in septic patients have
raised doubts as to whether conventional clinical and labo-
ratory criteria used for recruiting septic patients may
suffice in identifying groups of patients who would most
likely benefit from such therapies [3]. Because of these
problems, parameters that could provide early information
on the aetiology and severity of an inflammatory response
would be of interest. Such (a) marker(s) could also help
target the populations of septic patients who would
benefit from immunomodulatory trials.
Clinical data suggest that, whereas non-infectious inflam-
matory stimuli and viral infections produce only minor
increases in procalcitonin levels, generalized bacterial
infections produce large increases that seem to reflect the
severity of the infection [2,4]. Procalcitonin has been used
to differentiate infectious from non-infectious pancreatitis,
infectious from non-infectious aetiology of acute lung
injury, and in differentiating transplant rejection from
infectious complications after organ transplantation.
However, although procalcitonin offers considerable
advantages in comparison to conventionally used labora-
tory monitoring parameters, it does not fulfil all the criteria
of an ideal marker of severe microbial infections. Procalci-
tonin may not or may only slightly increase when infection
remains confined to a tissue or organ with no systemic
manifestations. This may be one of the reasons why calci-
tonin precursor levels in Steinwald’s study are very similar
in controls and less severe septic animals. Therefore, very
low levels of procalcitonin after the treatment of infection
do not always indicate complete eradication of the infec-
tion, and continuation of antibiotic therapy or surgical
measure may be necessary until all clinical signs of infec-
tion have disappeared. Furthermore, procalcitonin levels
may also be elevated after major trauma or surgery, after
cardiopulmonary bypass, and in patients with C-cell carci-
noma of the thyroid gland and small-cell carcinoma of the
lung [4].
Other important questions pertaining to procalcitonin
remain unanswered. Is procalcitonin release related to
bacterial products (alone) or do cytokines also play a role?
Which cells produce procalcitonin during severe infection?
What specific endocrinologic or immunologic (dys)func-
tion does procalcitonin serve during severe infections?
Because of these unanswered questions and limitations,
more clinical and laboratory studies are needed to uncover
the nature of this parameter in inflammatory states.
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